1354 related articles for article (PubMed ID: 33201207)
1. Bladder Cancer: A Review.
Lenis AT; Lec PM; Chamie K; Mshs MD
JAMA; 2020 Nov; 324(19):1980-1991. PubMed ID: 33201207
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of superficial bladder cancer.
Amling CL
Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
[TBL] [Abstract][Full Text] [Related]
3. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
4. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives in bladder cancer management.
Griffiths TR;
Int J Clin Pract; 2013 May; 67(5):435-48. PubMed ID: 23137019
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer.
Gwynn ES; Clark PE
Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
[TBL] [Abstract][Full Text] [Related]
9. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
[TBL] [Abstract][Full Text] [Related]
11. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
12. Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study.
Jian X; Shen M; Liao G
Medicine (Baltimore); 2019 Sep; 98(36):e16873. PubMed ID: 31490371
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].
Kausch von Schmeling I
Aktuelle Urol; 2010 Sep; 41(5):307-15. PubMed ID: 20824576
[TBL] [Abstract][Full Text] [Related]
14. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
[TBL] [Abstract][Full Text] [Related]
16. The clinical course of non-muscle invasive bladder cancer after transurethral resection of the tumor with or without subsequent intravesical application of bacillus Calmette-Guérin: The influence of patients gender and age.
Milošević R; Milović N; Aleksić P; Lazić M; Cerović S; Prelević R; Spasić A; Simić D; Kovačević B
Vojnosanit Pregl; 2015 Jul; 72(7):596-601. PubMed ID: 26364452
[TBL] [Abstract][Full Text] [Related]
17. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
18. Localized bladder cancer.
Izawa JI; Grossman HB
Curr Treat Options Oncol; 2000 Dec; 1(5):423-32. PubMed ID: 12057150
[TBL] [Abstract][Full Text] [Related]
19. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
20. Tackling non-muscle invasive bladder cancer in the clinic.
Woldu SL; Şanli Ö; Lotan Y
Expert Rev Anticancer Ther; 2017 May; 17(5):467-480. PubMed ID: 28359179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
